Endocrine Abstracts

Introduction: Somatostatin analogues (SSAs) are the mainstay treatment for carcinoid syndrome. ELECT is a large multinational phase 3 study evaluating rescue therapy use as a measure for control of carcinoid syndrome symptoms with LAN-ATG.Methods: Eligible patients had histologically-confirmed GEP-NETs and history of carcinoid syndrome, and were SSA-naïve or responsive to conventional doses of octreotide LAR (≤30 mg/4 weeks) or short-acting (&...

Background: SPINET was a phase 3 trial (NCT02683941) in patients with well-differentiated, advanced bronchopulmonary neuroendocrine tumors (NETs; typical and atypical carcinoids [TCs and ACs]). During the double-blind (DB) period, patients were randomized (2:1) to receive lanreotide autogel/depot (LAN; 120 mg) or placebo (PBO) every 28 days; in the optional open-label (OL) phase, all patients received LAN. Recruitment was stopped early due to slow accrual; all eligible patient...